THE POTENT AND SELECTIVE B3-ADRENOCEPTOR AGONIST MIRABEGRON IMPROVES PATIENT-REPORTED OUTCOMES IN OVERACTIVE BLADDER-RESULTS FROM TWO PHASE III STUDIES

被引：0
|
作者：
Nitti, V [1 ]
Herschorn, S. [2 ]
Auerbach, S. [3 ]
Khullar, V [4 ]
Amarenco, G. [5 ]
Blauwet, M. B. [6 ]
Boerrigter, P. [7 ]
Hakimi, Z. [8 ]
Siddiqui, E. [9 ]
Martin, N. [10 ]
机构：
[1] NYU Langone Med Ctr, Dept Urol, New York, NY USA
[2] Univ Toronto, Div Urol, Toronto, ON, Canada
[3] Hoag Mem Hosp, Newport Beach, CA USA
[4] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Urogynaecol Dept, London, England
[5] Hop Rothschild, Assistance Publ Hop Paris, Dept Neurol Rehabil, Urodynam & Neurophysiol Lab, F-75571 Paris, France
[6] Astellas Pharma Global Dev Inc, Biostat, Deerfield, IL USA
[7] Astellas Pharma Global Dev EU, Leiderdorp, Netherlands
[8] Astellas Pharma Europe, Leiderdorp, Netherlands
[9] Astellas Pharma Europe Ltd, Staines, Middx, England
[10] Astellas Sci & Med Affairs Inc, Deerfield, IL USA
来源：
NEUROUROLOGY AND URODYNAMICS | 2012年 / 31卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
68
引用
收藏
页码：813 / 815
页数：3
相关论文
共 50 条
  • [1] The Potent and Selective beta3-adrenoceptor Agonist Mirabegron Improves Patient-Reported Outcomes in the Treatment of Overactive Bladder
    Khullar, V
    Amarenco, G.
    Angulo, J.
    Boerrigter, P.
    Blauwet, M.
    Hakimi, Z.
    UROLOGY, 2012, 80 (03) : S123 - S123
  • [2] Patient-reported outcomes with the 3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder
    Khullar, Vik
    Amarenco, Gerard
    Angulo, Javier C.
    Blauwet, Mary Beth
    Nazir, Jameel
    Odeyemi, Isaac A.
    Hakimi, Zalmai
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 (08) : 987 - 994
  • [3] EFFICACY AND TOLERABILITY OF ONCE-DAILY MIRABEGRON, A POTENT AND SELECTIVE B3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER - RESULTS FROM A NORTH AMERICAN PHASE III TRIAL
    Nitti, V
    Herschorn, S.
    Lee, M.
    Martin, N.
    NEUROUROLOGY AND URODYNAMICS, 2011, 30 (06) : 927 - 929
  • [4] The efficacy and tolerability of the B3-adrenoceptor agonist mirabegron for the treatment of overactive bladder symptoms in older patients
    Giannantoni, Antonella
    Gubbiotti, Marilena
    NEUROUROLOGY AND URODYNAMICS, 2020, 39 : S64 - S65
  • [5] Mirabegron the first 3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies
    Chapple, Christopher
    BJU INTERNATIONAL, 2014, 113 (06) : 847 - 848
  • [6] MIRABEGRON IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME RESULTS FROM A NORTH-AMERICAN STUDY
    Nitti, Victor
    Herschorn, Sender
    Auerbach, Stephen
    Martin, Nancy
    Blauwet, Mary Beth
    Marshall, Thomas
    JOURNAL OF UROLOGY, 2011, 185 (04): : E784 - E784
  • [7] Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial
    Roberts, R.
    Bavendam, T.
    Glasser, D. B.
    Carlsson, M.
    Eyland, N.
    Elinoff, V.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (06) : 752 - 758
  • [8] Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
    Christopher R. Chapple
    Victor W. Nitti
    Vik Khullar
    Jean Jacques Wyndaele
    Sender Herschorn
    Philip van Kerrebroeck
    Mary Beth Blauwet
    Emad Siddiqui
    World Journal of Urology, 2014, 32 : 1565 - 1572
  • [9] Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
    Chapple, Christopher R.
    Nitti, Victor W.
    Khullar, Vik
    Wyndaele, Jean Jacques
    Herschorn, Sender
    van Kerrebroeck, Philip
    Blauwet, Mary Beth
    Siddiqui, Emad
    WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1565 - 1572
  • [10] Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial
    Khullar, Vik
    Amarenco, Gerard
    Angulo, Javier C.
    Cambronero, Javier
    Hoye, Kjetil
    Milsom, Ian
    Radziszewski, Piotr
    Rechberger, Tomasz
    Boerrigter, Peter
    Drogendijk, Ted
    Wooning, Marianne
    Chapple, Christopher
    EUROPEAN UROLOGY, 2013, 63 (02) : 283 - 295
12345